83389-27-9

Upstream product

• 5900-58-3 2-amino-4-chloro-benzoic acid methyl ester 
• 609-65-4 o-chlorobenzoyl chloride 

Downstream Products

• 83389-90-6 N'-[7-Chloro-2-(2-chloro-phenyl)-benzo[d][1,3]thiazin-(4Z)-ylidene]-hydrazinecarboxylic acid ethyl ester 
• 83389-59-7 [7-Chloro-2-(2-chloro-phenyl)-4-thioxo-4H-quinazolin-3-yl]-carbamic acid ethyl ester 
• 83390-05-0 [7-Chloro-2-(2-chloro-phenyl)-4-oxo-4H-quinazolin-3-yl]-carbamic acid ethyl ester 
• 83389-20-2 chloro-7 (chloro-2 phenyl)-2 benzothiazine-3,1 thione-4 

Relevant academic research and scientific papers

The evaluation and structure-activity relationships of 2-benzoylaminobenzoic esters and their analogues as anti-inflammatory and anti-platelet aggregation agents

Forty-seven 2-benzoylaminobenzoic esters were synthesized and evaluated in anti-platelet aggregation, inhibition of superoxide anion generation, and inhibition of neutrophil elastase release assays. Most 2-benzoylamino-4-chlorobenzoic acid derivatives showed selective inhibitory effects on arachidonic acid (AA)-induced platelet aggregation. Among them, compounds 6b and 7b exhibited more potent inhibitory effects (ca. 200-fold) than aspirin. Additionally, compounds 1a and 5a showed strong inhibitory effects on neutrophil superoxide generation with IC50 values of 0.65 and 0.17 μM, respectively. However, compounds 6d and 6e exhibited dual inhibitory effects on platelet aggregation and neutrophil elastase (NE) release; therefore, these two compounds may be new leads for development as anti-inflammatory and anti-platelet aggregatory agents.